These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 15464874

  • 21. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK.
    Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
    [Abstract] [Full Text] [Related]

  • 22. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
    Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ.
    Clin Cancer Res; 2006 May 15; 12(10):3092-8. PubMed ID: 16707607
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
    Gebbia V, Boussen H, Valerio MR.
    Anticancer Res; 2012 Feb 15; 32(2):529-36. PubMed ID: 22287742
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
    Kitamura T, Nishimatsu H, Hamamoto T, Tomita K, Takeuchi T, Ohta N.
    Expert Rev Anticancer Ther; 2002 Feb 15; 2(1):59-71. PubMed ID: 12113067
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
    Olver I, Keefe D, Myers M.
    Intern Med J; 2005 Jul 15; 35(7):405-8. PubMed ID: 15958110
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M, Sasagawa T, Tomita Y, Katagiri A, Morishita H, Saito T, Tanikawa T, Kawasaki T, Saito K, Nishiyama T, Kasahara T, Hara N, Takahashi K.
    Hinyokika Kiyo; 2003 Dec 15; 49(12):709-14. PubMed ID: 14978952
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 15; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 38. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
    Eklund J, Kozloff M, Vlamakis J, Starr A, Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M, Bergan RC.
    Cancer; 2006 Jun 01; 106(11):2459-65. PubMed ID: 16615097
    [Abstract] [Full Text] [Related]

  • 39. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
    Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, Goldhirsch A, D'Alessandro C, Cinieri S, Preda L, Colleoni M.
    Anticancer Drugs; 2006 Sep 01; 17(8):961-7. PubMed ID: 16940806
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.